Drugs / DA-1241
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03646721 | Aug 2018 → May 2020 | type 2 diabetes mellitus | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03061981 | Mar → Oct 2017 | type 2 diabetes mellitus | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06054815 | Sep 2023 → Oct 2024 | metabolic dysfunction-associated steatohepatitis | NeuroBo Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DA-1241 | “A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM” NCT03646721 ↗ |
| Route | Oral | “single oral dose of DA-1241” NCT03061981 ↗ |